Back to Awarded Treatment Trials


Awarded Trial: 07TGF-1097

Grant ID

07TGF-1097

Illness

Schizophrenia

Primary Drug/Intervention

Bexarotene

Primary Dosage

75 mg/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Lerner

Sample Size

90

Duration of Study Period for Each Subject

6 weeks

Outcome Measurements

PANSS, CGI, Simpson-Angus, CDSS, GAF, QLS, ESRS

Results

Bexarotene, a synthetic retinoid used to treat some cancers, was used as an adjunct to treat schizophrenia. 90 patients were given bexarotene 75 mg/d. or placebo for 6 weeks. 79 completed the study. Patients receiving bexarotene had a significant improvmenet on the PANSS positive subscale (p,.001) and on the Global Assessment of Functioning (p,.001). This thus confirms a previous smaller study.

Publication

Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, Benatov R, Ritsner MS. The Retinoid X Receptor Agonist Bexarotene Relieves Positive Symptoms of Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial. J Clin Psychiatry. 2013 Dec;74(12):1224-32.

Link

http://www.ncbi.nlm.nih.gov/pubmed/24434091

PI Name

Vladimir Lerner

Degree

MD

Center

N/A

Institution

Ben Gurion University of the Negev

Address

str. HaTsadik MiYerushalaim, 2

City or Town

Be'er Sheva

State or Province

N/A

Zip or Postal Code

84170

Country

Israel

Email Address

lernerv@bgu.ac.il